LEO Pharma
Manufacturing · Denmark · 4,084 Employees
View Company Info for Free
About
Headquarters
55 Industriparken, Ballerup, Region Hovedstaden...Phone Number
+45 44945888Website
www.leo-pharma.comRevenue
$1.6 BillionIndustry
Most Recent Scoops
Who is LEO Pharma
LEO Pharma Org Chart
Is LEO Pharma your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Check out if LEO Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
LEO Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if LEO Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if LEO Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once LEO Pharma has new funding data
Product Launch: Get notified when LEO Pharma launches new products
Earning: See what the market has to say on LEO Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at LEO Pharma
Recommended Actions
Reach out to Masked Content who joined LEO Pharma as Masked Content
Find 3 more new buyers
LEO Pharma Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
LEO Pharma Tech Stack
A closer look at the technologies used by LEO Pharma
Most Recent Scoops
LEO Pharma News & Media
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
FOSTER CITY, Calif. & BALLERUP, Denmark--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases. STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated tarMHRA Grants Marketing Authorisation for LEO Pharma’s Anzupgo® ▼(delgocitinib) cream in Great Britain
MAIDENHEAD, England--(BUSINESS WIRE)--MHRA Grants Marketing Authorisation for LEO Pharma’s Anzupgo® ▼(delgocitinib) cream in Great BritainLEO Pharma’s Anzupgo® (delgocitinib) Cream Achieves Marketing Approval in Switzerland
BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo® (delgocitinib) cream. The indication is for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults who have had an inadequate response to topical corticosteroids, or for whom potLEO Pharma gears for growth with senior leadership changes
LEO Pharma is excited to announce strategic leadership changes to bolster growth, further professionalize the organization, and strengthen its commitment to strategy and transformation. Kristian Sibilitz has been appointed as the new Executive Vice President (EVP) of Technical Development and Supply and will join the Global Leadership Team on December 1, 2024. Effective immediately, Jean Monin, EVP of Thrombosis, and Anne Jensen, Vice President (VP) of Strategy, will also join the Global Leaders
Frequently Asked Questions Regarding LEO Pharma
Founded in 2008, LEO Pharma is a multinational Danish pharmaceutical company specializing in dermatology.... Read More